Policy News Update: FDA’s IND Pilot, PDUFA VIII and CDMRP funding
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
The lies we tell ourselves about strategic partnerships – and what it really takes to run one
For years, conversations about clinical research sites have revolved around a familiar set of metrics, Paradigm’s Kurt Mussina shares his thoughts on why the most important question is actually; “How does a site actually operate?”
Beyond the Numbers: Kurt Mussina on Rethinking How Clinical Research Sites Are Evaluated
For years, conversations about clinical research sites have revolved around a familiar set of metrics, Paradigm’s Kurt Mussina shares his thoughts on why the most important question is actually; “How does a site actually operate?”
AMRC offers comments on FDA expedited Investigational New Drug (IND) pilot program
The Association for Multisite Research Corporations (AMRC) appreciates the opportunity to provide comments regarding FDA’s proposed Expedited Investigational New Drug (IND) Pilot Program. AMRC represents a nationwide network of leading clinical research organizations conducting research across a broad range of therapeutic areas and patient populations. Our members collectively operate 466 research sites across seven countries and engage millions of patients throughout the United States.
How MCRC’s improve clinical research for the patient, Sponsor, and investor: is private equity a threat to quality?
In this spirited roundtable discussion, leading clinical trial experts will debate how PE’s impact quality at sites.
Your trials are leaking money, and your sites know where
Join us for an in-depth conversation on effective strategies for growing your site within today’s evolving clinical research landscape. Hear from subject matter experts representing 3 leading site networks as they share proven approaches to expanding site business by leveraging multi-site network models.
EGR’s Lori Wright on impact, working with experts and learning somethingnew every day
Working hard, head down and concentrating on facing the next task or challenge, it can sometimes be easy to forget how important clinical trials are in the big picture of human health and their positive impact on alleviating suffering and prolonging the quality of life.
The Network Advantage: three Models, one Goal: scaling site success
Join us for an in-depth conversation on effective strategies for growing your site within today’s evolving clinical research landscape. Hear from subject matter experts representing 3 leading site networks as they share proven approaches to expanding site business by leveraging multi-site network models.
From PI to Pioneer: Jeff Kingsley’s Mission to Modernize Clinical Trials
Joining AMRC as a founding member in 2024 was an easy decision for Chief Development Officer Jeff Kingsley and the team at Centricity Research. They understood that working with AMRC members would give sites “a big voice with sponsors and regulators,” he says.
AMRC welcomes Panthera and ObjectiveHealth as members
The Association of Multisite Research Corporations (AMRC) today announces that Panthera and ObjectiveHealth have joined the organisation, bringing total membership to 19 multisite clinical research corporations (MCRCs), up from 14 members just 12 months ago.
